title: (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
abstract: The present study assessed the predictive value of (99m)Tc-3(poly-(ethylene glycol), PEG) 4-arginine-glycine-aspartic ((99m)Tc-3P-RGD2) single photon emission computed tomography (SPECT) for the early identification of response to antiangiogenic treatment with bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). Patients with advanced NSCLC treated with bevacizumab were prospectively studied with (99m)Tc-3P-RGD2 SPECT before and after 2 weeks from start of treatment. The tumor response was evaluated with RECIST criteria and related to observed change in the tumor to non-tumor (T/N) ratio for the largest known lesion. Receiver operating characteristic (ROC) curve analysis was used to determine T/N ratio changes with regard to predicting response to bevacizumab therapy. Change in T/N ratio was also related to progression-free survival (PFS) and overall survival (OS). Twenty-six patients were included, and 23 were finally assessable for metabolic response evaluation with (99m)Tc-3P-RGD2 SPECT. The cut-off value of T/N ratio change defined by ROC analysis was 24.4%. The sensitivity, specificity, and negative predictive value of (99m)Tc-3P-RGD2 SPECT for predicting tumor response were 81.8%, 91.7%, and 84.6%, respectively. Using the cut-off value defined by ROC analysis on (99m)Tc-3P-RGD2 SPECT, metabolic non-progressive disease patients (mNP) showed prolonged PFS (5.6 months versus 3.4 months; P < 0.001) and OS (17.1 months versus 8.6 months; P < 0.001) than metabolic progressive disease patients (mP). (99m)Tc-3P-RGD2 SPECT scan is a promising test to predict tumor response in patients with advanced non-small cell lung cancer early in the course of bevacizumab therapy.
authors.affiliation: Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University Changchun, Jilin, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Chen
authors.affiliation: Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University Changchun, Jilin, China.
authors.forename: Guoqing
authors.initials: G
authors.lastname: Zhao
authors.affiliation: Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University Changchun, Jilin, China.
authors.forename: Qingjie
authors.initials: Q
authors.lastname: Ma
authors.affiliation: Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University Changchun, Jilin, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Ji
authors.affiliation: Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University Changchun, Jilin, China.
authors.forename: Tiefeng
authors.initials: T
authors.lastname: Ji
authors.affiliation: Department of Thoracic Surgery, China-Japan Union Hospital, Jilin University Changchun, Jilin, China.
authors.forename: Hua
authors.initials: H
authors.lastname: Xin
authors.affiliation: Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University Changchun, Jilin, China.
authors.forename: Shi
authors.initials: S
authors.lastname: Gao
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D019540:Area Under Curve; D000068258:Bevacizumab / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015609:Organotechnetium Compounds / Q000008:administration & dosage*; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012372:ROC Curve; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D015609:Organotechnetium Compounds; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; C561921:technetium 99m (HYNIC-3PRGD(2))(tricine)(TPPTS); D000068258:Bevacizumab
keywords: 99mTc-3P-RGD2; SPECT; bevacizumab; non-small cell lung cancer; response